证券代码：600513 证券简称：联环药业 公告编号：2025-089 江苏联环药业股份有限公司 关于修订《公司章程》及修订、制定部分治理制度的公告 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 江苏联环药业股份有限公司（以下简称"公司"）于 2025 年 12 月 2 日召开 第九届董事会第十九次临时会议，审议通过了《关于修订<公司章程>的议案》、 《关于制定和修订公司部分治理制度的议案》。现就相关情况公告如下： 一、关于修订《公司章程》的情况 根据《中华人民共和国公司法》《上市公司章程指引》《上市公司治理准则》 等相关法律法规的规定，结合公司实际情况现拟对《公司章程》中的有关条款进 行相应修订，具体修订内容如下: | 修订前 | 修订后 | | --- | --- | | 第一条 为维护江苏联环药业股份有限 | 第一条 为维护江苏联环药业股份有限 | | 公司（以下简称"公司"或"本公司"）、 | 公司（以下简称"公司"或"本公司"）、 | | 公司股东和债权人的合法权益，规范公司的 | 公司股东、职工和债权人的合法权益， ...

证券代码：600513 证券简称：联环药业 公告编号：2025-090 江苏联环药业股份有限公司 关于续聘会计师事务所的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 | 1、事务所名称 | 中汇会计师事务所（特殊普通合伙） | | | | | --- | --- | --- | --- | --- | | 2、组织形式 | | 特殊普通合伙 | | | | 3、成立日期 | | 2013 年 | 12 月 | 19 日 | | 4、注册地址 | 杭州市上城区新业路8号华联时代大厦 | | | | | | 幢 601 室 | A | | | 2、人员信息 | 1、首席合伙人 | | | | 高峰 | | --- | --- | --- | --- | --- | | 2、2024 年末合伙人数量 | | | | 116 | | 3、2024 | 年末注册会计师数量 | | | 694 | | 其中：签署过证劵业务审计报告的注册会计师人数 | | | | 289 | | 近一年的变动情况 | | 合伙人较上年增加 | | ...

证券代码：600513 证券简称：联环药业 公告编号：2025-091 股东会召开日期：2025年12月22日 江苏联环药业股份有限公司 关于召开2025年第四次临时股东会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次股东会采用的网络投票系统：上海证券交易所股东会网络投票系统 一、召开会议的基本情况 (一)股东会类型和届次 2025年第四次临时股东会 (二)股东会召集人：董事会 (三)投票方式：本次股东会所采用的表决方式是现场投票和网络投票相结合 的方式 (四)现场会议召开的日期、时间和地点 召开的日期时间：2025 年 12 月 22 日 14 点 00 分 召开地点：扬州生物健康产业园健康一路 9 号联环药业会议室 (五)网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自2025 年 12 月 22 日 至2025 年 12 月 22 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东会召开当日的交易时间段，即 9 ...

Core Insights - The avian influenza concept sector experienced a decline of 0.76%, ranking among the top losers in the market, with major stocks like Zhongsheng Pharmaceutical hitting the limit down, while a few stocks like Wens Foodstuff and Weilan Biology saw gains of 1.80% each [1][2] Market Performance - The top-performing concept sectors included Titanium Dioxide with a gain of 4.31%, and Hainan Free Trade Zone with a gain of 3.54%, while the avian influenza sector was among the worst performers [1] - The avian influenza sector saw a net outflow of 784 million yuan, with 18 stocks experiencing net outflows, led by Zhongsheng Pharmaceutical with a net outflow of 684 million yuan [1] Stock Performance - Stocks with significant net outflows included: - Zhongsheng Pharmaceutical: -10.00% with a turnover rate of 18.78% and a net outflow of 683.65 million yuan - Yiling Pharmaceutical: -2.40% with a net outflow of 35.71 million yuan - Lianhuan Pharmaceutical: -1.79% with a net outflow of 25.69 million yuan - Hualan Biological: -6.60% with a net outflow of 18.13 million yuan [1] - Conversely, stocks with net inflows included: - Tiankang Biological: +1.26% with a net inflow of 16.52 million yuan - Shanghai Kaibao: -1.70% with a net inflow of 5.06 million yuan - Jinhai Biological: +0.16% with a net inflow of 3.82 million yuan [2]

Market Overview - The chemical pharmaceutical sector experienced a decline of 0.23% on November 20, with Minsheng Health leading the drop [1] - The Shanghai Composite Index closed at 3931.05, down 0.4%, while the Shenzhen Component Index closed at 12980.82, down 0.76% [1] Stock Performance - Notable gainers in the chemical pharmaceutical sector included: - Hainan Haiyao (000566) with a closing price of 7.92, up 10.00% and a trading volume of 2.1875 million shares, totaling 1.634 billion yuan [1] - Kangyi Pharmaceutical (300086) closed at 12.15, up 8.97% with a trading volume of 1.4039 million shares, totaling 1.656 billion yuan [1] - Other significant gainers included Bibete (688759), Yuekang Pharmaceutical (688658), and Qianyan Bio (688221) with increases ranging from 5.43% to 7.73% [1] - Conversely, the following stocks faced declines: - Minsheng Health (301507) closed at 16.69, down 6.18% with a trading volume of 273,400 shares, totaling 463 million yuan [2] - Shanhua Pharmaceutical (300452) and Hasa Lian (002900) also saw declines of 4.45% and 4.12% respectively [2] Capital Flow - The chemical pharmaceutical sector saw a net outflow of 1.233 billion yuan from institutional investors, while retail investors contributed a net inflow of 964 million yuan [2] - Notable capital flows included: - Hainan Haiyao (000566) had a net inflow of 25.3 million yuan from institutional investors, but a net outflow of 101 million yuan from retail investors [3] - Kangyi Pharmaceutical (300086) experienced a net inflow of 56.4 million yuan from institutional investors, while retail investors saw a net outflow of 67.9 million yuan [3]

Market Overview - The chemical pharmaceutical sector experienced a decline of 1.44% on November 19, with Hainan Haiyao leading the drop [1] - The Shanghai Composite Index closed at 3946.74, up 0.18%, while the Shenzhen Component Index closed at 13080.09, unchanged [1] Stock Performance - Notable gainers in the chemical pharmaceutical sector included: - Shanhe Pharmaceutical (300452) with a closing price of 15.07, up 9.04% and a trading volume of 390,200 shares, totaling 586 million yuan [1] - ST Suhao (600200) closed at 1.02, up 5.15% with a trading volume of 429,200 shares [1] - ST Jingfeng (000908) closed at 66.8, up 5.02% with a trading volume of 354,800 shares [1] - Major decliners included: - Muan Nanhai (000566) with a closing price of 7.20, down 10.00% and a trading volume of 2,192,500 shares, totaling 1.625 billion yuan [2] - Sitaili (603520) closed at 10.66, down 6.74% with a trading volume of 315,600 shares [2] - Yatai Pharmaceutical (002370) closed at 7.79, down 6.59% with a trading volume of 1,044,700 shares [2] Capital Flow - The chemical pharmaceutical sector saw a net outflow of 2.278 billion yuan from institutional investors, while retail investors contributed a net inflow of 2.139 billion yuan [2] - The top stocks by net inflow from institutional investors included: - Changshan Pharmaceutical (300255) with a net inflow of 71.90 million yuan, accounting for 6.20% of total inflow [3] - Xingqi Eye Medicine (300573) with a net inflow of 70.33 million yuan, representing 12.29% [3] - Shanhe Pharmaceutical (300452) with a net inflow of 68.13 million yuan, making up 11.62% [3]

Core Viewpoint - The company plans to sign a technology cooperation development contract with Nanjing University to jointly develop an anti-thrombotic small nucleic acid drug, with a total contract amount of 15 million RMB (including tax) [1] Company Summary - The company will pay the cooperation fees to Nanjing University in installments according to the project development plan outlined in the contract [1] - Upon successful development and market launch of the target drug, the company will pay a percentage of the annual revenue from the drug to Nanjing University for a period of 10 years [1] - The collaboration aims to leverage Nanjing University's strong research capabilities in nucleic acid drugs and the company's industrialization and clinical development capabilities to advance the research and commercialization of innovative drugs [1] Industry Summary - The domestic small nucleic acid drug market is primarily dominated by imported drugs, indicating significant growth potential in the domestic market compared to the global market [1] - With increasing policy support and capital investment, the development of small nucleic acid drugs in China is progressing rapidly, suggesting an imminent surge in the domestic market [1] - The company's strategic focus on cardiovascular treatments aligns well with the development of the new drug, enhancing its core competitiveness in research and injecting new momentum into its innovative drug portfolio [1]

Core Viewpoint - The company plans to sign a technology cooperation development contract with Nanjing University to jointly develop anti-thrombotic small nucleic acid drugs, with a total contract amount of 15 million RMB (including tax) [1] Group 1: Company Strategy - The company will pay the cooperation fees to Nanjing University in installments according to the project development plan [1] - Upon successful development and market launch of the target drug, the company will pay a percentage of the annual revenue from the drug to Nanjing University for a period of 10 years [1] - The collaboration aims to leverage Nanjing University's strong research capabilities in nucleic acid drugs and the company's industrialization and clinical development capabilities to advance the research and commercialization of innovative drugs [1] Group 2: Market Opportunity - The domestic small nucleic acid drug market is primarily dominated by imported drugs, indicating significant growth potential in the domestic market compared to the global market [1] - With increasing policy support and capital investment, the development of domestic small nucleic acid drugs is progressing rapidly, and the market is expected to experience rapid growth [1] - The company aims to seize market opportunities by understanding local market demands and developing products tailored to domestic patients, aligning with its strategic planning in the cardiovascular treatment field [1]

Core Viewpoint - The company, Lianhuan Pharmaceutical, announced a collaboration with Nanjing University to develop "anti-thrombotic small nucleic acid drugs" with an investment of 15 million yuan [1] Group 1: Collaboration Details - The project is currently in the preliminary research stage and involves signing a technical cooperation development contract with Nanjing University [1] - The collaboration aims to conduct various preclinical research phases, including pharmacodynamic validation and drug-like property assessment of the target sequence [1] Group 2: Research Complexity - The research and development process is complex and involves multiple uncertainties, indicating potential challenges ahead [1]

证券代码：600513 证券简称：联环药业 公告编号：2025-087 江苏联环药业股份有限公司 关于拟签订重大合同暨关联交易事项的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： （二）交易目的和原因 当前国内小核酸药物市场以进口药物为主，国内市场相较于全球市场有较大 的发展空间。随着政策支持与资本投入的不断增加，国内小核酸药物研发进展迅 速，在全球市场蓬勃发展、国内市场即将迎来快速增长的背景下，公司计划尽早 布局小核酸药物领域，有望抢占市场先机，凭借对本土市场需求的深入理解，精 准开发契合国内患者的产品。同时该药物与公司心脑血管治疗领域的战略规划深 度适配，既有利于提升公司研发层面的核心竞争力，也能为创新药产品储备注入 新动能，推动公司在该领域持续深耕。 ●江苏联环药业股份有限公司（以下简称"联环药业"或"公司"）拟以自 有资金 1,500.00 万元人民币与南京大学合作开展"抗血栓小核酸药物"联合研 发（以下简称"本项目"），并与南京大学签订《技术合作开发合同》。 ●本项目目前处于前期研究阶段，后续仍 ...